hHER2*ex20ins-IRES-Luc-2A-EGFP

Export PDF

Strain Information

Cell Line

hHER2*ex20ins-IRES-Luc-2A-EGFP

Cat. NO.

NM-YD09

Model Description

derived from R26-CAG-LSL-hHER2*ex20ins-IRES-Luc-2A-EGFP mice (NM-KI-190071) spontaneous breast cancer model

Strain State

Validation of tumorigenic capacity completed

Validation Data

image.png

Fig1. The genotype of hHER2*ex20ins-IRES-Luc-2A-EGFP cell was identified by PCR

WT: wild-type cells; H2O: negative water control; 100bp DNA marker from Transgen (BM311)

image.png

Fig2. Tumor growth curve in hHER2*ex20ins-IRES-Luc-2A-EGFP subcutaneously transplanted tumor model (n=9)  

image.png

Fig3. Body weight change in hHER2*ex20ins-IRES-Luc-2A-EGFP subcutaneously transplanted tumor model (n=9)

image.png

Fig4. Bioluminescence imaging of hHER2*ex20ins-IRES-Luc-2A-EGFP subcutaneously transplanted tumor model at the end of timepoint

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more